Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

NCT05870865 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this clinical trial is to evaluate ASN008 in people with itch caused by eczema. The main questions it aims to answer are: * What is the efficacy and safety of ASN008? * What is the impact of ASN008 on itch in patients with atopic dermatitis? Participants will be asked to apply topical ASN008, or matching vehicle (placebo containing no active drug), to their eczema lesions twice daily for 4 weeks. Researchers will compare 3 different doses of ASN008 and a matching vehicle group to see which group responds best.

Interventions

  • DRUG ASN008
  • OTHER ASN008 Matching Vehicle

Study Locations (20)

California

  • TrialSpark Investigative Site 0123 — Beverly Hills
  • TrialSpark Investigative Site 0113 — Fremont
  • TrialSpark Investigative Site 0101 — Los Angeles

Florida

  • TrialSpark Investigative Site 0103 — Miami Lakes
  • TrialSpark Investigative Site 0129 — Miramar

Indiana

  • TrialSpark Investigative Site 0131 — Clarksville
  • TrialSpark Investigative Site 0109 — Indianapolis

Louisiana

  • TrialSpark Investigative Site 0108 — Baton Rouge
  • TrialSpark Investigative Site 0124 — Monroe

New York

  • TrialSpark Investigative Site 0115 — Kew Gardens
  • TrialSpark Investigative Site 0119 — New York

Arizona

  • TrialSpark Investigative Site 0106 — Scottsdale

Arkansas

  • TrialSpark Investigative Site 0118 — Hot Springs

Kentucky

  • TrialSpark Investigative Site 0112 — Louisville

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2023-05-03
Est. Completion 2023-12-28
Phase Phase 2

Sponsor

Formation Bio

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05870865

The ClinicalTrials.gov registry entry for NCT05870865 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Formation Bio, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Dermatitis, Atopic appearing as the primary indexed condition, and to 2 interventions — of which ASN008 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05870865 reports 20 study locations spanning 14 distinct geographic areas — top geographies include California, Florida, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05870865 about?

NCT05870865 is a clinical study titled "A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis". The goal of this clinical trial is to evaluate ASN008 in people with itch caused by eczema. The main questions it aims to answer are: * What is the efficacy and safety of ASN008? * What is the impact of ASN008 on itch in patients with atopic dermatitis? Participants will be asked to apply topical A...

What is the current status of trial NCT05870865?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2023-05-03. Estimated completion is 2023-12-28.

What conditions does trial NCT05870865 study?

This clinical trial studies the following conditions: Dermatitis, Atopic, Pruritus. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05870865?

The interventions under investigation include: ASN008 (DRUG), ASN008 Matching Vehicle (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05870865?

This trial is sponsored by Formation Bio, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05870865 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial